EUVIMEDOpdag EUVIMED
VergleichsstudieOpen access · CC BY 4.0

Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing

Luca Mastorino iD, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Yingying Liao, Francesco Leo, Pietro Quaglino iD, Simone Ribero iD

Experimental Dermatology · 2025-02 · 34 (2)

DOI: 10.1111/exd.70062 ↗

At a glance

Vergleichsstudie in Experimental Dermatology, published online on 2025-02-16. Written by Luca Mastorino and 7 co-authors. Institution: Dermatologic Clinic, Departement of Clinical Medicine, University of Turin, Turin, Italy. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Cited 12 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The possibility of modulating the treatment regimen regarding dose reduction (de‐escalation) or dose augmentation (escalation) in psoriasis biological treatment has been of increasing interest. De‐escalation strategies include reducing the single therapeutic dose, the mg/kg ratio or the number of injections, or dose‐spacing (D‐S), that is, extending the interval between administrations. Data regarding dose de‐escalation, in particular D‐S, on IL‐23, are lacking to date. The present pilot study is a cohort study with a retrospective analysis of the general characteristics and effectiveness outcomes of psoriatic patients undergoing therapeutic biologic D‐S of risankizumab and guselkumab. Ninety‐four patients, 32 (34.04%) treated with guselkumab and 62 (65.96%) treated with risankizumab, underwent dose modulation by D‐S of 50% of the approved range. The mean PASI decreased from 12.15 (5.43 SD) to 0.15 (0.46 SD) at D‐S time. Attainment of PASI100 was rapid: 88.3% at the D‐S date, remaining stable over the following year, reaching 100% of patients observed 12 months after D‐S. Similar is the trend for PASI 90 and PASI

Subjects

MeSH terms (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHumansPilot ProjectsFemaleMaleMiddle AgedRetrospective StudiesAdultTreatment OutcomeAgedDrug Administration ScheduleDose-Response Relationship, DrugSeverity of Illness Index

Author keywords

IL‐17 inhibitorsIL‐23 inhibitorsbiologicsde‐escalationdose spacingpsoriasis

Substances

risankizumabguselkumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Authors and institutions

  • Dermatologic Clinic, Departement of Clinical Medicine, University of Turin, Turin, Italy.

ORCID profiles: Luca Mastorino, Pietro Quaglino, Simone Ribero

Cite

APA

Mastorino, L., Dapavo, P., Ortoncelli, M., Bongiovanni, E., Liao, Y., Leo, F., Quaglino, P., & Ribero, S. (2025). Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing. Experimental Dermatology, 34(2). https://doi.org/10.1111/exd.70062

Vancouver

Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Leo F, et al. Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing. Experimental Dermatology. 2025;34(2). doi:10.1111/exd.70062

BibTeX
@article{Mastorino2025,
  author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Bongiovanni, Eleonora and Liao, Yingying and Leo, Francesco and Quaglino, Pietro and Ribero, Simone},
  title = {Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing},
  journal = {Experimental Dermatology},
  year = {2025},
  volume = {34},
  number = {2},
  doi = {10.1111/exd.70062}
}
Start for free →